Protalix BioTherapeutics Inc (AMEX:PLX)
$ 1.1 -0.15 (-12%) Market Cap: 80.65 Mil Enterprise Value: 62.37 Mil PE Ratio: 55.00 PB Ratio: 2.39 GF Score: 60/100

Q4 2019 Protalix Biotherapeutics Inc Earnings Call Transcript

Mar 12, 2020 / 12:30PM GMT
Release Date Price: $2.39 (+1.27%)
Operator

Greetings, and welcome to the Protalix Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial and Business Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Monique Kosse, Investor Relations at LifeSci Advisors. Thank you. You may begin.

Monique Kosse
LifeSci Advisors, LLC - MD

Thank you, operator, and welcome, everyone. Thank you for joining us today for a discussion of Protalix' Fourth Quarter and Full Year 2019 Financial Results. Leading the call today will be Dror Bashan, President and Chief Executive Officer of Protalix. He will be joined by Eyal Rubin, Chief Financial Officer of Protalix.

Before we begin, I would like to remind everyone that various statements made during this call will include forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those regarding the company's future plans, prospects and strategy,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot